Saitama, Japan

Tomoyuki Yoneta

This inventor holds 2 USPTO granted patents. Top assignees: Zeria Pharmaceutical Co., Ltd., Zeria Pharmaceuticals Co., Ltd.. Active years: 2001-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tomoyuki Yoneta. Retrieved from https://idiyas.com/inventor/tomoyuki-yoneta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 44(Granted Patents)


Location History:

  • Osato-gun, JP (2001)
  • Saitama, JP (2002)

Company Filing History:


Years Active: 2001-2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tomoyuki Yoneta: Innovator in Benzodiazepine Derivatives

Introduction

Tomoyuki Yoneta is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of benzodiazepine derivatives. With a total of 2 patents to his name, his work has had a meaningful impact on medicinal chemistry.

Latest Patents

Yoneta's latest patents focus on 1,5-benzodiazepine derivatives. These patents include innovations represented by formula (I), salts thereof, and medicines containing these compounds as active ingredients. His research in this area has opened new avenues for therapeutic applications.

Career Highlights

Throughout his career, Tomoyuki Yoneta has worked with Zeria Pharmaceutical Co., Ltd. and Zeria Pharmaceuticals Co., Ltd. His experience in these companies has allowed him to contribute to the advancement of pharmaceutical sciences and the development of new medications.

Collaborations

Yoneta has collaborated with esteemed colleagues such as Katsuo Shinozaki and Masakazu Murata. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Tomoyuki Yoneta's work in the field of benzodiazepine derivatives exemplifies the importance of innovation in pharmaceuticals. His contributions continue to influence the development of new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…